87052324

Information

• Trademark
• 87052324

• Source

• Serial Number

  87052324

• Registration Number

  5332632

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 31 - Grains and agricultural, horticultural and forestry products not included in other classes
  • 40 - Treatment of materials
  • 42 - Scientific and technological services and research and design relating thereto

• Filing Date

  May 27, 2016
  8 years ago

• Registration Date

  November 14, 2017
  7 years ago

• Transaction Date

  July 03, 2024
  6 months ago

• Status Date

  May 28, 2024
  7 months ago

• Published for Opposition Date

  August 29, 2017
  7 years ago

• Location Date

  November 14, 2017
  7 years ago

• Status Code

  710

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  BLAZICH, JOAN MICHELE

• Attorney Docket Number

  60895-403227

  Attorney Name

  Mark Harrison

  Law Office Assigned Location Code

  N40

• Owners

  • CRESCENDO BIOLOGICS LTD

Case File Statements

• GS0401: Treatment and transformation of materials for others, namely, the manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; custom manufacture of therapies using antibodies and antibody fragments
• DM0000: The mark consists of a circle which has a u-shaped portion missing from its central top.
• GS0051: Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ and tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; monoclonal antibody therapeutic preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ and tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; antibodies and antibody fragments being diagnostic reagents for medical and veterinary diagnostics; antibodies and antibody fragments for use in the discovery, preclinical and clinical development of therapeutic products; antibodies and antibody fragments being therapeutic pharmaceuticals for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ and tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases for use in the manufacture of therapeutic products
• CC0000: Color is not claimed as a feature of the mark.
• GS0011: Chemicals for use in industry and science; chemicals test kits for in vitro testing for laboratory research purposes; biochemicals, namely, monoclonal antibodies and antibody fragments all being proteins for in vitro scientific and laboratory research use; biochemicals, namely, monoclonal antibodies and antibody fragments all being proteins for scientific and laboratory research use; biochemical, namely, monoclonal antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical and clinical development of therapeutic products
• GS0421: Scientific and technological services, namely, scientific research, analysis and testing, and research and design in the field of therapeutic pharmaceuticals; scientific laboratory services; laboratory services in the field of antibodies and antibody fragments; research in the field of the development of antibodies and antibody fragments; provision of scientific information in the field of antibodies and antibody fragments for medical and veterinary purposes; engineering of antibodies and antibody fragments; scientific services, namely, the discovery, preclinical and clinical development of therapeutic products; consultancy services relating thereto, namely, therapeutic products
• GS0311: Live animals; live mice

Case File Event Statements

• 9/15/2016 - 8 years ago

  6 - NON-FINAL ACTION E-MAILED Type: GNRT

• 5/31/2016 - 8 years ago

  1 - NEW APPLICATION ENTERED Type: NWAP

• 6/4/2016 - 8 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 6/7/2016 - 8 years ago

  3 - NOTICE OF DESIGN SEARCH CODE E-MAILED Type: MDSC

• 9/12/2016 - 8 years ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 9/15/2016 - 8 years ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 9/15/2016 - 8 years ago

  7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 10/28/2016 - 8 years ago

  17 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3

• 10/20/2016 - 8 years ago

  8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 10/20/2016 - 8 years ago

  9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 10/20/2016 - 8 years ago

  10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 10/28/2016 - 8 years ago

  11 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 10/28/2016 - 8 years ago

  12 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 10/28/2016 - 8 years ago

  13 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 10/28/2016 - 8 years ago

  14 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 10/28/2016 - 8 years ago

  16 - LETTER OF SUSPENSION E-MAILED Type: GNSL

• 6/9/2017 - 7 years ago

  21 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI

• 7/18/2017 - 7 years ago

  22 - ASSIGNED TO LIE Type: ALIE

• 7/19/2017 - 7 years ago

  23 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 7/19/2017 - 7 years ago

  24 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 8/9/2017 - 7 years ago

  26 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 8/29/2017 - 7 years ago

  27 - PUBLISHED FOR OPPOSITION Type: PUBO

• 8/29/2017 - 7 years ago

  28 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 11/14/2017 - 7 years ago

  29 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 11/14/2022 - 2 years ago

  30 - COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Type: REM1

• 5/28/2024 - 7 months ago

  31 - CANCELLED SEC. 8 (6-YR) Type: C8..

• 7/26/2017 - 7 years ago

  25 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 10/28/2016 - 8 years ago

  15 - SUSPENSION LETTER WRITTEN Type: CNSL

• 4/28/2017 - 7 years ago

  18 - SUSPENSION INQUIRY WRITTEN Type: CNSI

• 4/28/2017 - 7 years ago

  19 - INQUIRY TO SUSPENSION E-MAILED Type: GNSI

• 4/28/2017 - 7 years ago

  20 - NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Type: GNS2